NKTR

Nektar Therapeutics (NKTR) | Rumor.io

Nektar Therapeutics

NKTR

Attention (50-day avg)0.02%

Attention rank (50-day avg)#321

Bullish sentiment (50-day avg)70%

Price to earnings ratio-6.21

Market capitalization2.1B

Earnings per share-6.12

Dividend yield (TTM)—

Revenue (annual)55.2M

Net income (annual)-164.1M

Social

What share of all stock conversation is about NKTR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.08% +0.03	0.06% +0.04	0.02% +0.01	0.01% +0

Sep 28

$NKTR pre-announced positive 24-week AA OT data, which may lead to a decent stock price movement.
Two Seas Capital increased its ownership stake in $NKTR to 9.8%, contrary to expectations that they would be selling ahead of the $LLY news.
$NKTR is set to present new data from the REZOLVE-AA study at EADV, including 6-month off-treatment data for patients with severe-to-very-severe atopic dermatitis.

Generated by AI

Sentiment

Of the messages about NKTR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	93.94% -6.06	57.95% -5.01	66.73% -21.24	76.07% -7.88
Bearish	6.06% +6.06	42.05% +5.01	33.27% +21.24	23.93% +7.88

Bullish· Jun 2

Nektar Therapeutics is a potential takeover target, making it a "steal" at current prices.
The company's Treg therapy has the potential to be a blockbuster, and the failure of JAK inhibitors is a "wake-up call" for the industry.
The stock is due for a bounce, with a potential entry point near the 200-day moving average and a possible breakout after upcoming conference and index addition.

Bearish· Jun 2

The market is ascribing a low value to Nektar Therapeutics' pipeline, with an estimated enterprise value (EV) of around $1B.
The stock's decline may be driven by margin calls and forced selling, particularly in the wake of the ABVX disaster.
Nektar Therapeutics' stock price has fallen significantly, with some analysts predicting a buyout or acquisition, potentially driven by pressure from 13G filers and shareholders who purchased shares at higher prices.

Generated by AI

Topics

Of the messages about NKTR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	40.98%	29.6%	29.73%	39.59%
Controversies	1.64%	66.08%	64.85%	25.91%
Technical Analysis	0%	0.05%	0.43%	4.57%
Analysts	0%	0.16%	2.47%	15.71%
Earnings	57.38%	3.65%	1.99%	1.45%
Macro	0%	0.47%	0.54%	12.76%

Earnings· Nov 5

Nektar Therapeutics will release earnings after the market closes on Wednesday.
Analysts expect a loss of -0.73 EPS.
Earnings release is scheduled for after the market closes on Wednesday.

Analysts· Jun 25

H.C. Wainwright analyst Arthur He raised the firm's price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating on the shares.
Jefferies analyst Roger Song raised the firm's price target on Nektar to $69 from $2 and keeps a Buy rating on the shares after the company's REZOLVE-AD study met all endpoints.
BTIG analyst raised the firm's price target on Nektar to $100 from $60 and maintains a Buy rating on the shares.

Announcements· Apr 20

Nektar Therapeutics (NKTR) announced positive Phase 2b data for rezpegaldesleukin in severe alopecia areata, with 29% and 31% of patients achieving a SALT Score less than or equal to 20.
The company plans to submit the REZOLVE-AA results for presentation at a medical conference in 2026 and has launched a $250M equity offering to fund R&D and Phase 3 trials.
Nektar Therapeutics stock surged to over four-year highs after reporting encouraging 52-week topline results from its mid-stage trial for patients with severe alopecia areata, with the price up 24.72% since the alert.

Controversies· Oct 15

The pre-trial hearing and jury trial for Nektar Therapeutics' (NKTR) lawsuit against Eli Lilly (LLY) have been delayed due to the government shutdown, with a new date set for at least after December 11.
The delay in the trial and pre-trial conference has led to speculation that LLY may be negotiating a buyout of NKTR, although this is purely speculative.
If NKTR were to win the lawsuit, a settlement of around $650 million could have a significant impact on the company's EV and eliminate the trial burden.

Technical Analysis· Jun 25

The current price of $NKTR is $26.15, and the stock has been acting as strong support at $17-$19.50; the next key level to test is $30-$32.30.
The breakout zone for $NKTR is $33.50-$35.75, with targets at $39.80, $42.20, and $45.00+; the stock has a strong resistance at $37.
The stock has a tiny float of 8.3M, 68% insider ownership, and has already enrolled in a Phase 3 trial for Descartes-08 targeting Myasthenia Gravis, which could lead to a 30-50% move like $NKTR did.

Generated by AI

Community

Of the messages about NKTR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	98.77%	84.45%	91.05%	69.29%
Newcomers	1.23%	15.55%	8.95%	30.71%

Regulars· Sep 28

Nektar Therapeutics has announced three oral presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026, including new data from the REZOLVE-AA study.
The REZOLVE-AA study's 6-month off-treatment data for patients with severe-to-very-severe atopic dermatitis is expected to be presented at EADV, which could lead to a decent move in the stock price.
Nektar Therapeutics has a high short interest of over 17%, and Two Seas Capital has increased its position in the company to 9.8%.

Newcomers· Apr 22

The price of Nektar Therapeutics ($NKTR) stock may be impacted by the recent capital increase, with some investors believing it will lead to higher prices in the long term.
Nektar's lead drug, rezpegaldesleukin, is being developed for atopic dermatitis and alopecia areata, and some investors believe it has potential as a broad first-line option.
The market's reaction to Nektar's data and capital increase is uncertain, with some investors wondering if it will lead to a repeat pattern of price spikes followed by grinding down, while others believe it will ultimately result in higher prices.

Generated by AI

Nektar Therapeutics (NasdaqCM:NKTR) plans three oral presentations on rezpegaldesleukin at the European Academy of Dermatology & Venereology Congress 2026. The talks will share 6‑month off‑treatment durability data from the Phase 2b REZOLVE-AA trial in severe alopecia areata. Multi‑omic biomarker findings from atopic dermatitis patients on rezpegaldesleukin are also scheduled for presentation at EADV 2026. The new rezpegaldesleukin durability and biomarker readouts come in addition to a...

10h agoYahoo Finance

Nektar to present alopecia areata drug data at EADV congress

1d agoInvesting.com

Nektar Therapeutics (NKTR) Dropped, So What Is Driving Attention Now?

2d agoYahoo Finance

A Jury Awarded Nektar $90 Million From Eli Lilly. Here’s Why the Stock Barely Moved

Key Stats for Eli Lilly StockCurrent Price: $1,183. 46Target Price (Mid): ~$2,060Street Target: ~$1,325Potential Total Return: ~74%Annualized IRR: ~14% / yearWhat Happened?Eli Lilly and Company (LLY) closed essentially flat at $1,183.

3d agoYahoo Finance

Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says

4d agoReuters

Update: Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal

(Updates to add Eli Lilly's response in the fifth and sixth paragraphs.) Nektar Therapeutics (NK

4d agoYahoo Finance

Also Discussed

Investors talking about NKTR also mention

#	Name	Attention
1	Abivax SAABVX	0.01%-0.01
2	Apogee Therapeutics, Inc. - Common StockAPGE	0%0
3	uniQure N.V.QURE	0.02%+0.01
4	Corvus Pharmaceuticals Inc.CRVS	0.01%-0.01
5	Revolution Medicines, Inc.RVMD	0.01%-0.01
6	Q32 Bio Inc.QTTB	0%+0
7	IDEAYA Biosciences Inc.IDYA	0%-0.01
8	Wave Life Sciences Ltd.WVE	0%+0
9	Incyte Corp.INCY	0%new
10	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02

Nektar Therapeutics

Healthcare
Biotechnology

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunology and oncology medicines. Nektar Therapeutics’ current pipeline centers on therapies designed to address immune system dysfunction in autoimmune and chronic inflammatory diseases, with its lead candidate, rezpegaldesleukin, being evaluated in clinical programs for conditions such as atopic dermatitis, alopecia areata, and type 1 diabetes. The company also advances additional candidates across autoimmune, fibrotic, and cancer-related areas, including programs targeting ulcerative colitis, vitiligo, multiple sclerosis, and solid tumors. Through its proprietary chemistry and immunology expertise, Nektar Therapeutics develops highly selective therapeutic candidates intended to modulate key biological pathways and support precision treatment approaches across specialty disease areas.

Website

Location

455 Mission Bay Boulevard South

San Francisco, CA, 94158

United States

Social

What share of all stock conversation is about NKTR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.08% +0.03	0.06% +0.04	0.02% +0.01	0.01% +0

Sep 28

$NKTR pre-announced positive 24-week AA OT data, which may lead to a decent stock price movement.
Two Seas Capital increased its ownership stake in $NKTR to 9.8%, contrary to expectations that they would be selling ahead of the $LLY news.
$NKTR is set to present new data from the REZOLVE-AA study at EADV, including 6-month off-treatment data for patients with severe-to-very-severe atopic dermatitis.

Generated by AI

Sentiment

Of the messages about NKTR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	93.94% -6.06	57.95% -5.01	66.73% -21.24	76.07% -7.88
Bearish	6.06% +6.06	42.05% +5.01	33.27% +21.24	23.93% +7.88

Bullish· Jun 2

Nektar Therapeutics is a potential takeover target, making it a "steal" at current prices.
The company's Treg therapy has the potential to be a blockbuster, and the failure of JAK inhibitors is a "wake-up call" for the industry.
The stock is due for a bounce, with a potential entry point near the 200-day moving average and a possible breakout after upcoming conference and index addition.

Bearish· Jun 2

The market is ascribing a low value to Nektar Therapeutics' pipeline, with an estimated enterprise value (EV) of around $1B.
The stock's decline may be driven by margin calls and forced selling, particularly in the wake of the ABVX disaster.
Nektar Therapeutics' stock price has fallen significantly, with some analysts predicting a buyout or acquisition, potentially driven by pressure from 13G filers and shareholders who purchased shares at higher prices.

Generated by AI

Topics

Of the messages about NKTR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	40.98%	29.6%	29.73%	39.59%
Controversies	1.64%	66.08%	64.85%	25.91%
Technical Analysis	0%	0.05%	0.43%	4.57%
Analysts	0%	0.16%	2.47%	15.71%
Earnings	57.38%	3.65%	1.99%	1.45%
Macro	0%	0.47%	0.54%	12.76%

Earnings· Nov 5

Nektar Therapeutics will release earnings after the market closes on Wednesday.
Analysts expect a loss of -0.73 EPS.
Earnings release is scheduled for after the market closes on Wednesday.

Analysts· Jun 25

H.C. Wainwright analyst Arthur He raised the firm's price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating on the shares.
Jefferies analyst Roger Song raised the firm's price target on Nektar to $69 from $2 and keeps a Buy rating on the shares after the company's REZOLVE-AD study met all endpoints.
BTIG analyst raised the firm's price target on Nektar to $100 from $60 and maintains a Buy rating on the shares.

Announcements· Apr 20

Nektar Therapeutics (NKTR) announced positive Phase 2b data for rezpegaldesleukin in severe alopecia areata, with 29% and 31% of patients achieving a SALT Score less than or equal to 20.
The company plans to submit the REZOLVE-AA results for presentation at a medical conference in 2026 and has launched a $250M equity offering to fund R&D and Phase 3 trials.
Nektar Therapeutics stock surged to over four-year highs after reporting encouraging 52-week topline results from its mid-stage trial for patients with severe alopecia areata, with the price up 24.72% since the alert.

Controversies· Oct 15

The pre-trial hearing and jury trial for Nektar Therapeutics' (NKTR) lawsuit against Eli Lilly (LLY) have been delayed due to the government shutdown, with a new date set for at least after December 11.
The delay in the trial and pre-trial conference has led to speculation that LLY may be negotiating a buyout of NKTR, although this is purely speculative.
If NKTR were to win the lawsuit, a settlement of around $650 million could have a significant impact on the company's EV and eliminate the trial burden.

Technical Analysis· Jun 25

The current price of $NKTR is $26.15, and the stock has been acting as strong support at $17-$19.50; the next key level to test is $30-$32.30.
The breakout zone for $NKTR is $33.50-$35.75, with targets at $39.80, $42.20, and $45.00+; the stock has a strong resistance at $37.
The stock has a tiny float of 8.3M, 68% insider ownership, and has already enrolled in a Phase 3 trial for Descartes-08 targeting Myasthenia Gravis, which could lead to a 30-50% move like $NKTR did.

Generated by AI

Community

Of the messages about NKTR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	98.77%	84.45%	91.05%	69.29%
Newcomers	1.23%	15.55%	8.95%	30.71%

Regulars· Sep 28

Nektar Therapeutics has announced three oral presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026, including new data from the REZOLVE-AA study.
The REZOLVE-AA study's 6-month off-treatment data for patients with severe-to-very-severe atopic dermatitis is expected to be presented at EADV, which could lead to a decent move in the stock price.
Nektar Therapeutics has a high short interest of over 17%, and Two Seas Capital has increased its position in the company to 9.8%.

Newcomers· Apr 22

The price of Nektar Therapeutics ($NKTR) stock may be impacted by the recent capital increase, with some investors believing it will lead to higher prices in the long term.
Nektar's lead drug, rezpegaldesleukin, is being developed for atopic dermatitis and alopecia areata, and some investors believe it has potential as a broad first-line option.
The market's reaction to Nektar's data and capital increase is uncertain, with some investors wondering if it will lead to a repeat pattern of price spikes followed by grinding down, while others believe it will ultimately result in higher prices.

Generated by AI

Nektar Therapeutics

Social

Sep 28

Bullish· Jun 2

Bearish· Jun 2

Earnings· Nov 5

Analysts· Jun 25

Announcements· Apr 20

Controversies· Oct 15

Technical Analysis· Jun 25

Regulars· Sep 28

Newcomers· Apr 22

What Could Nektar Therapeutics (NKTR) New Rezpegaldesleukin Data Mean For Its Case?

Nektar to present alopecia areata drug data at EADV congress

Nektar Therapeutics (NKTR) Dropped, So What Is Driving Attention Now?

A Jury Awarded Nektar $90 Million From Eli Lilly. Here’s Why the Stock Barely Moved

Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says

Update: Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal

Also Discussed

Nektar Therapeutics

Company Information

Location

What Could Nektar Therapeutics (NKTR) New Rezpegaldesleukin Data Mean For Its Case?

Nektar to present alopecia areata drug data at EADV congress

Nektar Therapeutics (NKTR) Dropped, So What Is Driving Attention Now?

A Jury Awarded Nektar $90 Million From Eli Lilly. Here’s Why the Stock Barely Moved

Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says

Update: Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal

Also Discussed

Social

Sep 28

Bullish· Jun 2

Bearish· Jun 2

Earnings· Nov 5

Analysts· Jun 25

Announcements· Apr 20

Controversies· Oct 15

Technical Analysis· Jun 25

Regulars· Sep 28

Newcomers· Apr 22